Literature DB >> 12761104

Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1.

Satoshi Ishikawa1, Kazuyoshi Kawahara, Yutaka Kagami, Yasunori Isshiki, Aki Kaneko, Hidenori Matsui, Nobuhiko Okada, Hirofumi Danbara.   

Abstract

Shiga toxin 1 (Stx1) of enterohemorrhagic Escherichia coli O157:H7 was cloned, and four mutant Stx1s were constructed by site-directed mutagenesis with PCR. The wild-type and mutant Stx1s with amino acid replacements at positions 167 and 170 of the A subunit were purified by one-step affinity chromatography with commercially available Globotriose Fractogel, and the mutant Stxs were used for the immunization of mice. The mutant toxins were nontoxic to Vero cells in vitro and to mice in vivo and induced the immunoglobulin G antibody against the wild-type Stx1, which neutralized the cytotoxicity of Stx1. The induced antibody titers depended on the mutation at position 170 of the A subunit. The mice immunized with the mutant Stx1s were protected against a challenge of approximately 100 times the 50% lethal dose of the wild-type Stx1, suggesting that the mutant toxins are good candidates for toxoid vaccines for infection by Stx1-producing E. coli.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761104      PMCID: PMC155758          DOI: 10.1128/IAI.71.6.3235-3239.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Binding of avian ovomucoid to shiga-like toxin type 1 and its utilization for receptor analog affinity chromatography.

Authors:  M Miyake; E Utsuno; M Noda
Journal:  Anal Biochem       Date:  2000-06-01       Impact factor: 3.365

2.  Molecular analysis of enterohemorrhagic Escherichia coli isolates in Japan and its application to epidemiological investigation.

Authors:  H Watanabe; J Terajima; H Izumiya; A Wada; K Tamura
Journal:  Pediatr Int       Date:  1999-04       Impact factor: 1.524

3.  Single-step method for purification of Shiga toxin-1 B subunit using receptor-mediated affinity chromatography by globotriaosylceramide-conjugated octyl sepharose CL-4B.

Authors:  H Nakajima; Y U Katagiri; N Kiyokawa; T Taguchi; T Suzuki; T Sekino; K Mimori; M Saito; H Nakao; T Takeda; J Fujimoto
Journal:  Protein Expr Purif       Date:  2001-07       Impact factor: 1.650

4.  Cross-protection against challenge by intravenous Escherichia coli verocytotoxin 1 (VT1) in rabbits immunized with VT2 toxoid.

Authors:  K Ludwig; M A Karmali; C R Smith; M Petric
Journal:  Can J Microbiol       Date:  2002-01       Impact factor: 2.419

5.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice.

Authors:  E Konadu; A Donohue-Rolfe; S B Calderwood; V Pozsgay; J Shiloach; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

8.  Immunoprophylactic potential of cloned Shiga toxin 2 B subunit.

Authors:  P Marcato; G Mulvey; R J Read; P N Nation; G D Armstrong
Journal:  J Infect Dis       Date:  2000-12-27       Impact factor: 5.226

9.  Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection.

Authors:  Evelyn A Dean-Nystrom; Lisa J Gansheroff; Melody Mills; Harley W Moon; Alison D O'Brien
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

10.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

View more
  16 in total

1.  Protective immunization of mice with an active-site mutant of subtilase cytotoxin of Shiga toxin-producing Escherichia coli.

Authors:  Ursula M Talbot; James C Paton; Adrienne W Paton
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

2.  Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge.

Authors:  Ulrike Beate Mayr; Christoph Haller; Wolfgang Haidinger; Alena Atrasheuskaya; Eugenij Bukin; Werner Lubitz; Georgy Ignatyev
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Immunization with non-toxic variants of Shiga toxin type 2 (Stx2) generates high titers of protective antibodies.

Authors:  E V Loukianov; L A Zacharova; O S Khasanova; F K Khasanov; Yu V Kozlov
Journal:  Dokl Biochem Biophys       Date:  2015-03-13       Impact factor: 0.788

Review 4.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis.

Authors:  Somshuvra Mukhopadhyay; Adam D Linstedt
Journal:  Science       Date:  2012-01-20       Impact factor: 47.728

6.  Protection against hemorrhagic colitis in an animal model by oral immunization with isogeneic rabbit enteropathogenic Escherichia coli attenuated by truncating intimin.

Authors:  Tonia S Agin; Chengru Zhu; Laura A Johnson; Timothy E Thate; Zhuolu Yang; Edgar C Boedeker
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli.

Authors:  Robert L G Rojas; Priscila A D P Gomes; Leticia V Bentancor; Maria E Sbrogio-Almeida; Sérgio O P Costa; Liliana M Massis; Rita C C Ferreira; Marina S Palermo; Luís C S Ferreira
Journal:  Clin Vaccine Immunol       Date:  2010-02-10

8.  A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model.

Authors:  Leticia V Bentancor; Marcos Bilen; Romina J Fernández Brando; María Victoria Ramos; Luis C S Ferreira; Pablo D Ghiringhelli; Marina S Palermo
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

Review 9.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

10.  Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7.

Authors:  Víctor A García-Angulo; Anjana Kalita; Mridul Kalita; Luis Lozano; Alfredo G Torres
Journal:  Infect Immun       Date:  2014-03-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.